Whistler Conference Centre Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2009



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Targeted Cancer Therapies (X8)


Organizer(s) Barbara L. Weber and Gregory L. Verdine
March 27—April 1, 2009
Whistler Conference Centre • Whistler, British Columbia Canada
Abstract Deadline: Dec 1, 2008
Late Abstract Deadline: Dec 29, 2008
Scholarship Deadline: Dec 1, 2008
Early Registration Deadline: Jan 27, 2009

Sponsored by Amgen Inc. and Genentech BioOncology

Joint Meeting: Antibodies as Drugs (X7)

Summary of Meeting:
Recent advances in targeted therapy have unequivocally demonstrated the activity of these compounds in cancer patients. Following on the clinical successes of imitanib and trastuzumab, pharmaceutical companies have filled their oncology pipelines with small molecule kinase inhibitors. Work on identifying the most active agents for specific tumor types and increasing efficacy with combination targeted therapy has become the primary focus of translational oncology research. However, this field is in its infancy, with much to be learned about which molecules to target, how to go beyond kinase inhibitors, how to optimize dose and scheduling of these new classes of drugs and how to tailor therapy to the genetic architecture of individual tumors. This conference will bring together experts in the key disciplines of cell biology, biochemistry, molecular genetics, medicinal chemistry, imaging and clinical oncology to identify critical problems that may best be addressed using a multidisciplinary approach and foster those collaborations.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


FRIDAY, MARCH 27

15:00—19:30
Registration

Foyer
18:30—19:30
Refreshments

Foyer
19:30—20:30
Keynote Address (Joint)
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom B,C
* James D. Marks, University of California, San Francisco, USA

* Barbara L. Weber, Tango Therapeutics, USA

David P. Lane, Experimental Therapeutic Centre, Singapore
Target Validation in Cancer Treatment: The Use of Chemical Biology and Protein Aptamer Approaches


SATURDAY, MARCH 28

07:00—08:00
Breakfast

Sea to Sky Ballroom A, Lower Level
07:00—08:00
Poster Setup

Foyer/Mountain View/Sea to Sky Ballroom A
08:00—11:15
Novel Cancer Drug Scaffolds (Joint)
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom B,C
* James E. Bradner, Novartis Institutes for BioMedical Research, USA

* James D. Marks, University of California, San Francisco, USA

Andreas G. Plückthun, University of Zürich, Switzerland
Ankyrin Repeat Proteins

Nick Terrett, Ensemble Discovery Corporation, USA
A DNA-Programmed Chemistry Approach to Macrocyclic Lead Compounds

Gregory L. Verdine, Harvard University, USA
Drugging “Undruggable” Targets Using Stapled Peptides

Rodney W. Lappe, CovX Research LLC, Pfizer, USA
Using CovX-Body Technology to Target the Angiopoietin Axis

Yollete V. Guillen Schlippe, Massachusetts General Hospital, USA
Short Talk: Selection of Cyclic Peptides Composed of Multiple Unnatural Amino Acids that Display Antibody-Like Affinity

Jennifer R. Cochran, Stanford University, USA
Short Talk: Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects

09:20—09:40
Coffee Break

Foyer
11:15—12:00
Lunch

Foyer/Sea to Sky Ballroom A
12:00—14:30
Poster Session 1

Foyer/Mountain View/Sea to Sky Ballroom A
14:30—16:30
Workshop 1: Novel Approaches to Cancer Drug Development (Joint)

Sea to Sky Ballroom C
* Louis M. Weiner, Georgetown University Medical Center, USA

Steve K. Horrigan, Avalon Pharmaceuticals, USA
Systems Biology for Lead Optimization

Lutz Jermutus, MedImmune LLC, UK
Discovering Cancer Therapeutics by Phage and Ribosome Display as well as Transgenics Technologies

Ravi Majeti, Stanford University, USA
Blocking Monoclonal Antibodies Directed Against CD47 Preferentially Enable Phagocytosis and Elimination of Human Acute Myeloid Leukemia Stem Cells

Teemu T. Junttila, Genentech, Inc., USA
Superior in vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2 Amplified Breast Cancer

Mariia Yuneva, Francis Crick Institute, UK
Combining Metabolomics with Microarray Analysis to Determine Metabolic Cancer Targets in vivo

16:30—17:00
Coffee Available

Foyer
17:00—19:15
The Chemistry of Targeted Drug Discovery
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom C
* Gregory L. Verdine, Harvard University, USA

James E. Bradner, Novartis Institutes for BioMedical Research, USA
Next-Generation Histone Deacetylase Inhibitors

Saul H. Rosenberg, Abbott Laboratories, USA
Targeting Apoptosis: Bcl-2 Family Protein Inhibitors

Nathanael Gray, Dana-Farber Cancer Center, USA
Tackling the Kinome: Bcr-Abl, EML4-ALK in EGFR

Kathlynn C. Brown, University of Texas Southwestern Medical Center, USA
Short Talk: Isolation of a Suite of Cell Binding Peptides: Novel Ligands for Diagnosis and Targeted Therapy for Non-Small Cell Lung Cancer

Suzanne Forry-Schaudies, National Cancer Institute, National Institutes of Health, USA
Short Talk: NCI Chemical Biology Consortium (CBC)


Following Session is for Antibodies as Drugs (X7)

17:00—19:00
Generating and Engineering Novel Antibody Binding Sites
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom B
* Lutz Jermutus, MedImmune LLC, UK

George Georgiou, University of Texas at Austin, USA
Selection, Fc Engineering and Preparative Expression of Full Length IgG in E.coli

James D. Marks, University of California, San Francisco, USA
Selecting Internalizing Antibodies for Drug Delivery

Max Woisetschlager, F-Star, Austria
Antigen Binding by Modified Immunoglobulin Fc (Fcab) and Complete IgGs with Additional Binding Sites

Roger R. Beerli, NBE-Therapeutics AG, Switzerland
Short Talk: Isolation and Preclinical Validation of Therapeutic Human Monoclonal Antibodies Isolated by Mammalian Cell Display

19:15
On Own for Dinner


SUNDAY, MARCH 29

07:00—08:00
Breakfast

Sea to Sky Ballroom A, Lower Level
08:00—11:15
Cancer Targets
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom C
* Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA

Craig B. Thompson, Memorial Sloan Kettering Cancer Center, USA
Mitochondrial Targets

Pierre Sonveaux, University of Louvain, Medical School, Belgium
Lactate-Fueled Tumor Cell Respiration: A New Paradigm and a New Target for Therapy

Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
Role of Feedback and Redundancy in Oncoprotein Activated Signaling Pathways

D. Gary Gilliland, Merck & Co., Inc., USA
Genome Wide shRNA-Based Synthetic Lethality Screens to Target "Undruggable" Cancer Disease Alleles

Daniel Monticello, Molecular Logix Inc, USA
Short Talk: Development of a Pan-HER Dominant Negative Ligand that Inhibits HER Phosphorylation and HER-Ligand Dependent Tumor Cell Growth

Peter R. Rhode, Altor BioScience Corp., USA
Short Talk: IL-15 Superagonist as a Targeted Immunotherapeutic Molecule


Following Session is for Antibodies as Drugs (X7)

08:00—11:15
Engineering Fc Regions for Optimized ADCC and PK
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom B
* Raphael Clynes, Xencor, Inc., USA

Louis M. Weiner, Georgetown University Medical Center, USA
Optimizing in vitro and in vivo ADCC for Cancer Therapy

John R. Desjarlais, Xencor, USA
Engineered Fc Domains for Enhanced Cytotoxicity and Pharmacokinetics

Pablo Umaña, Roche Innovation Center Zürich, Switzerland
New Glycoengineered Antibodies with Enhanced Effector Functions

E. Sally Ward, University of Texas Southwestern Medical Center, USA
The Role of FcRn in IgG Homeostasis: Implications for the Use of Antibodies in Therapy

Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands
Short Talk: The Fc Receptor gamma-Chain ITAM is Required for Antibody Immunotherapy

Shu-ichi Hashimoto, Chiome Bioscience Inc., Japan
Short Talk: ADLib System: New Antibody Generating Technology based on Cell Surface Displayed Antibody Library

09:20—09:40
Coffee Break

Foyer
11:15
On Own for Lunch

11:15—13:00
Poster Setup

Foyer/Mountain View/Sea to Sky Ballroom A
13:00—22:00
Poster Viewing

Foyer/Mountain View/Sea to Sky Ballroom A

Following Session is for Antibodies as Drugs (X7)

14:30—16:30
Workshop 2: Bispecific Antibodies and Antibody Combinations: The How and the Why

Sea to Sky Ballroom B
* James D. Marks, University of California, San Francisco, USA

Robert Mabry, ZymoGenetics, Inc., USA
Selection of Stable Antibody Fragments for Assembly of Dual-Targeting Therapeutics

Carston R. Wagner, University of Minnesota, USA
Chemically Controlled Assembly of Single-Chain Antibody Nanorings

Wei Yan, Amgen Inc., USA
Design and Engineering of Fc Heterodimers for the Production of Bispecific Antibodies

Aran Frank Labrijn, Genmab, Netherlands
Therapeutic IgG4 Antibodies Engage in Fab-Arm Exchange with Patient’s IgG4 in vivo

Ann P. MacLaren, Biogen Idec, USA
A Novel Tetravalent Anti-CD23 Antibody Induces Potent Anti-Tumor Activity in CD23+ Tumor Cells via Hyper Cross-Linking of CD23

Klaus Koefoed, Symphogen A/S, Denmark
Development of Sym004 - a Dual Antibody Combination Targeting the Epidermal Growth Factor Receptor with Strong Anti-Tumor Efficacy in a Xenograft Mouse Model

Rob Roovers, Merus BV, Netherlands
Combining Different Modes of EGFR Inhibition into a Single Nanobody-Based Molecule Yields a Promising Anti-Cancer Drug

16:30—17:00
Coffee Available

Foyer
17:00—19:00
Autophagy and Metabolism
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom C
Matthew G. Vander Heiden, Massachusetts Institute of Technology, USA
Targeting Cancer Cell Metabolism

Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA
Targeting Energy Sensing

Chi Van Dang, University of Pennsylvania, USA
Therapeutic Implications of the Warburg Effect


Following Session is for Antibodies as Drugs (X7)

17:00—19:00
Immune System Activation to Elicit Therapeutic Responses
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom B
* E. Sally Ward, University of Texas Southwestern Medical Center, USA

Raphael Clynes, Xencor, Inc., USA
Conversion of Passive Antibody Therapy to Active Immunity

Gerard Zurawski, Baylor Institute for Immunology Research, USA
Vaccines Based on Targeting Antigens Directly to DCs

Kavita Dhodapkar, Yale University, USA
Antibody-Based Induction of Adaptive Immune Response

Mark S. Cragg, University of Southampton, UK
Short Talk: The Role of Activatory and Inhibitory FcgR in Antibody Immunotherapy

19:00—20:00
Social Hour with Lite Bites

Foyer/Mountain View/Sea to Sky Ballroom A
19:30—22:00
Poster Session 2

Foyer/Mountain View/Sea to Sky Ballroom A

MONDAY, MARCH 30

07:00—08:00
Breakfast

Sea to Sky Ballroom A, Lower Level
08:00—11:15
Novel Target Discovery
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom C
* D. Gary Gilliland, Merck & Co., Inc., USA

Alan Ashworth, Institute of Cancer Research, UK
Synthetic Lethal Approaches to the Development of New Therapies Targeting DNA Repair Deficiencies in Cancer

William G. Kaelin, Jr., Dana-Farber Cancer Institute, USA
Therapeutic Targets Emerging from Studies of the VHL Tumor Suppressor Protein and 2-Oxoglutarate Dependent Dioxygenases

Peter A. Jones, Van Andel Research Institute, USA
Epigenetic Therapy

Lynda Chin, University of Texas MD Anderson Cancer Center, USA
Mining and Translating the Cancer Genome

Igor Landais, Oregon Health Sciences University, USA
Short Talk: Identification of Potent Inhibitors of the Fanconi Anemia Pathway Using a Novel Cell-Free Assay

Johannes Zuber, Research Institute of Molecular Pathology, Austria
Short Talk: In-vivo Evaluation of Putative Drug Targets in Chemotherapy-Resistant MLL/AF9-Induced Acute Myeloid Leukemia Using Tet-Regulatable RNAi


Following Session is for Antibodies as Drugs (X7)

08:00—11:15
Antibodies for Treatment of Cancer
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom B
* Louis M. Weiner, Georgetown University Medical Center, USA

Mark X. Sliwkowski, Genentech, Inc., USA
HER2 Targeted Therapies

Andrew M. Scott, Ludwig Institute for Cancer Research, Australia
Targeting a Novel EGFR Epitope on Cancer Cells

Kerry A. Chester, University College London Cancer Institute, UK
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) of Cancer

Philip E. Thorpe, University of Texas Southwestern Medical Center, USA
Targeting Exposed Phosphatidylserine on Cancer Blood Vessels: Preclinical and Clinical Studies

Kelly J. Davis, Massachusetts Institute of Technology, USA
Short Talk: Antibody with Picomolar Affinity to DOTA Chelates of Multiple Radionuclides for Pretargeted Radioimmunotherapy

Mitsuo Satoh, Research Division, Kyowa Hakko Kirin Company Ltd., Japan
Short Talk: Non-Fucosylated Rituximab Potentiates Human Neutrophil Phagocytosis through its High Binding for FcgammaRIIIb and MHC Class II Expression on the Phagocytotic Neutrophils

09:20—09:40
Coffee Break

Foyer
11:15—13:00
Poster Setup

Foyer/Mountain View/Sea to Sky Ballroom A
11:15
On Own for Lunch

13:00—22:00
Poster Viewing

Foyer/Mountain View/Sea to Sky Ballroom A

Following Session is for Antibodies as Drugs (X7)

14:30—16:30
Workshop 3: Therapeutic Antibodies in the Neurosciences

Sea to Sky Ballroom B
* Eric V. Shusta, University of Wisconsin, Madison, USA
Antibodies and the Blood-Brain Barrier

Anne Messer, Wadsworth Center, USA
Intrabodies for Neurodegeneration Disorders

Anthony Williamson, Calmune Corporation, USA
Antibodies for Prion Based Diseases

Angela R. Jones, University of Wisconsin - Madison, USA
Short Talk: Identification of Blood-Brain Barrier Targeting and Transporting Antibodies

16:30—17:00
Coffee Available

Foyer
17:00—19:15
Target Validation
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom C
* William G. Kaelin, Jr., Dana-Farber Cancer Institute, USA

Dean Walton Felsher, Stanford University, USA
Validating Cancer Targets using Conditional Transgenic Mouse Models

Dean Walton Felsher, Stanford University, USA
Validating Cancer Targets using Conditional Transgenic Mouse Models

Scott W. Lowe, Memorial Sloan Kettering Cancer Center, USA
Dissecting Tumor Suppressor Gene Networks in vivo

Peter J. Houghton, St. Jude Children's Research Hospital, USA
Tumor Xenografts for Target Validation

Poulikos I. Poulikakos, Memorial Sloan-Kettering Cancer Center, USA
Short Talk: ATP-Competitive Inhibitors of RAF Kinase Inhibit ERK Signaling in Cells Harboring Mutant BRAF, but Activate ERK Signaling in Cells with Wild Type BRAF

Amy R. Rappaport, Cold Spring Harbor Laboratory, USA
Short Talk: MLL/AF9 is Required for the Maintenance of Aggressive Acute Myeloid Leukemia in Mice


Following Session is for Antibodies as Drugs (X7)

17:00—19:00
Identifying and Predicting Antibody Efficacy and Toxicity
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom B
* Andrew M. Scott, Ludwig Institute for Cancer Research, Australia

Peter D. Senter, Seattle Genetics Inc., USA
Antibody Drug Conjugates for Cancer Therapy

Birgit Schoeberl, Merrimack Pharmaceuticals, USA
An Attempt to Translate in vitro Responses into the Clinic Using Computationally Predicted Preclinical Data from ErbB Targeted Therapies

Richard H.J. Begent, University College London, UK
Guidelines for Information about Antibody Therapy Experiments; Lessons from the Tegenero Experience

Max Warncke, Novartis, Switzerland
Short Talk: Effector Functions of Human IgG Subclasses for Non-Human Primate FcgR

19:00—20:00
Social Hour with Lite Bites

Foyer/Mountain View/Sea to Sky Ballroom A
19:30—22:00
Poster Session 3

Foyer/Mountain View/Sea to Sky Ballroom A

TUESDAY, MARCH 31

07:00—08:00
Breakfast

Sea to Sky Ballroom A, Lower Level
08:00—11:00
Translating Targeted Therapy to the Clinic
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom C
* Lynda Chin, University of Texas MD Anderson Cancer Center, USA

Alan Colowick, Gloucester Pharmaceuticals, USA
Clinical Activity of Romidepsin, a pan-HDACi, in the Clinic

Barbara L. Weber, Tango Therapeutics, USA
Using Cancer Genomics to Inform Targeted Drug Development

Tak W. Mak, Campbell Family Institute for Breast Cancer, Canada
Cancer Metabolism: Back to the Future

Alice Fan, Stanford University, USA
Talk Title to be Determined

Paul Spellman, Lawrence Berkeley National Laboratory, USA
Talk Title to be Determined

Phillip G. Febbo, Genomic Health, Inc., USA
Short Talk: MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through 4EBP1-Mediated Inhibition of Autophagy


Following Session is for Antibodies as Drugs (X7)

08:00—11:15
Antibodies in the Treatment of Autoimmunity, Allergy and Infectious Diseases
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom B
* James D. Marks, University of California, San Francisco, USA

Ian A. Wilson, The Scripps Research Institute, USA
Structural Aspects of Antibody Recognition of Influenza

Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Human Monoclonal Antibodies from Memory B cells

Dennis R. Burton, The Scripps Research Institute, USA
Antibodies for HIV Therapy and Vaccine Development

John Haurum, Imclone, USA
Capturing the Natural Humoral Immune Response by Symplex

Tariq Ghayur, AbbVie Inc., USA
Dual Variable Domain Immunoglobulins (DVD-Ig TM): A Novel Class of Dual-Specific Biologics

09:20—09:40
Coffee Break

Foyer
11:00
On Own for Lunch

16:30—17:00
Coffee Available

Foyer
17:00—19:00
Imaging in Cancer Drug Discovery (Joint)
Meeting has ended...abstracts no longer viewable online.

Sea to Sky Ballroom B,C
* E. Sally Ward, University of Texas Southwestern Medical Center, USA

* Roger Y. Tsien, HHMI/University of California, San Diego, USA
Optical and MR Imaging of Tumors in vivo with Activatable Cell Penetrating Peptides

Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Pretargeted Radioimmunotherapy: Predictive Modeling and Experimental Validation

Anna M. Wu, University of California, Los Angeles, USA
Engineered Antibodies for Probing Cell Surface Markers in vivo

Sripad Ram, University of Texas Southwestern Medical Center, USA
Short Talk: 3D Single Molecule Tracking of Antibodies in Live Cells Using Multifocal Plane Microscopy

19:00—20:00
Social Hour with Lite Bites

20:00—23:00
Entertainment

Foyer/Mountain View/Sea to Sky Ballroom A

WEDNESDAY, APRIL 1

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge additional support for this conference from:

Cell Signaling Technology, Inc. Educational donation provided by Amgen
Genentech BioOncology Lilly Singapore Centre for Drug Discovery

Genentech, Inc.
 

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Abbott Laboratories


GlaxoSmithKline


Merck & Co., Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Cell Press Royal Society of Chemistry

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676